News from mabvax therapeutics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

( OTC-BB:TELK,OTC-QB:TELK)

Feb 03, 2016, 08:00 ET

MabVax Therapeutics to Present at BIO CEO & Investor Conference

 MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage immuno-oncology drug development company, announces that President and...

Feb 01, 2016, 10:37 ET

MabVax Therapeutics Receives FDA Authorization for Phase I Clinical Trial with 89Zr-HuMab-5B1 as PET Imaging Agent for Pancreatic Cancer

 MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage oncology drug-development company, announces receipt of notice from the...

Jan 19, 2016, 08:00 ET

MabVax Therapeutics Holdings Executes a Debt Facility for up to $10 million

 MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage immuno-oncology drug development company announced today that it has closed...

Jan 06, 2016, 08:00 ET

MabVax Therapeutics Files IND for a Phase I Clinical Trial with 89Zr-HuMab-5B1

MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage oncology drug development company, announces the filing of an Investigational...

Jan 04, 2016, 08:00 ET

MabVax Therapeutics Announces FDA Authorization to Proceed with HuMab-5B1 in a Phase I Clinical Trial for the Treatment for Pancreatic Cancer

 MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage oncology drug development company, announces that it has received notice...

Dec 01, 2015, 09:00 ET

MabVax Therapeutics Files IND for Phase I Clinical Trial with HuMab 5B1 as a Therapeutic for Pancreatic Cancer

 MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage oncology drug development company, announces it has filed an...

Nov 03, 2015, 08:00 ET

MabVax Therapeutics Completes Manufacturing of HuMab 5B1 for Upcoming Phase I Clinical Trials

 MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage oncology drug development company, announces it has completed manufacturing...

Oct 21, 2015, 08:00 ET

MabVax Therapeutics HuMab 5B1 Antibody Featured in Five Presentations at the World Molecular Imaging Congress

MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) a clinical-stage oncology drug development company announces its antibody, HuMab 5B1 was featured...

Oct 20, 2015, 08:00 ET

MabVax Therapeutics to Hold Investor Webcast and Conference Call on Thursday, October 22nd at 11:00 am EDT

 MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage immuno-oncology drug development company announced today its CEO, David...

Oct 05, 2015, 16:31 ET

MabVax Therapeutics Holdings, Inc. Announces Closing of Public Offering

MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) ("MabVax"), a clinical-stage immuno-oncology drug development company, today announced that it has...

Sep 30, 2015, 09:39 ET

MabVax Therapeutics Holdings, Inc. Announces Pricing of Public Offering

 MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) ("MabVax"), a clinical-stage immuno-oncology drug development company, today announced the...

Aug 31, 2015, 10:00 ET

MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations

MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) aclinical stage oncology drug development company announces that the Company's lead antibody,...

Aug 10, 2015, 08:00 ET

MabVax Therapeutics Holdings Provides Corporate Update and Reports Second Quarter 2015 Financial Results

 MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage oncology drug development company, today provided a corporate update and...

Aug 06, 2015, 08:00 ET

MabVax Therapeutics and The Rockefeller University Enter Into a Collaborative Research Agreement

MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage oncology drug development company, and The Rockefeller University's Laboratory...

Aug 05, 2015, 08:00 ET

MabVax Therapeutics Issues Letter to Stockholders

 MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) ("MabVax" or the "Company"), a clinical stage immuno-oncology drug development company,...

May 28, 2015, 08:00 ET

MabVax Therapeutics Holdings to Present at the 2015 LD Micro Invitational Investor Conference on June 2nd at 4:30 PM EDT

MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage immuno-oncology drug development company, announced today that its President and...

May 05, 2015, 08:00 ET

MabVax Therapeutics' Human Antibody Clinical Development Candidate HuMab 5B1 Successfully Clears Important Early Toxicology Testing

 MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage oncology drug development company, announced today it has received the...

Apr 07, 2015, 08:00 ET

MabVax Therapeutics Appoints Tom Varvaro to its Board of Directors

MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) ("MabVax" or "Company"), a clinical-stage cancer immunotherapy company, announced today that Tom...

Apr 06, 2015, 09:36 ET

MabVax Therapeutics Announces Closing of Financing

 MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) ("MabVax" or "Company"), a clinical-stage cancer immunotherapy company, is pleased to...

Mar 26, 2015, 08:00 ET

MabVax Therapeutics Enters Into Exchange Agreements To Issue Common Stock and Series D Preferred Stock Eliminating Series A-1 and B Convertible Preferred and Related Warrants

 MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), acancer diagnostic and immunotherapy company, today announced that it had successfully...